Loading clinical trials...
Loading clinical trials...
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study
Conditions
Interventions
Iadademstat
Gilteritinib Oral Tablet
Locations
13
United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
The University of Arizona Cancer Center - North Campus
Tucson, Arizona, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Miami Cancer Institute
Miami, Florida, United States
The John Hopkins University School of Medicine
Baltimore, Maryland, United States
Massachusetts General Hospital (MGH)
Boston, Massachusetts, United States
Start Date
November 14, 2022
Primary Completion Date
November 30, 2025
Completion Date
November 30, 2025
Last Updated
July 29, 2024
NCT04716452
NCT06459024
NCT06297941
NCT05190471
NCT06532084
NCT06125652
Lead Sponsor
Oryzon Genomics S.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions